Exelixis, Inc. (EXEL) Stock Price & Analysis

Exelixis, Inc. (EXEL) closed at USD 65.31 on Thursday, October 22, 2026, up 1.13% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 64.58; the Oct 22, 2026 session ranged USD 64.33–65.5 on volume of 1,709,173 shares. Market capitalization is $16.18B, with a 52-week range of USD 36–65.5 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.

Also available as compact Markdown for AI agents: nexqual.com/EXEL.md

Key facts (EXEL)

• Last four reported quarters (through Jul 3, 2026): revenue $2.44B, net income $861M (35.3% margin), free cash flow $1.17B (SEC filings).
• Valuation: P/E 18.8x (avg 23.6x at the last 3 fiscal year-ends).
• 1 of 80 tracked superinvestors hold EXEL (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
• Insider open-market sales, last ~7 months: 10 Form 4 filings, $11.1M; 6 not under a Rule 10b5-1 plan ($9.6M); 3 by opportunistic insiders (2 outside 10b5-1 plans), 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.67 on a 1–5 scale) (18 analysts), mean target USD 55.53 (range 41–70).
• Total return with dividends: 1Y +71.6% vs S&P 500 +14.9%; 5Y +205.2% vs S&P 500 +80.3%.
• Next earnings: 2026-10-29, EPS estimate USD 0.9, revenue estimate $650M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (EXEL)

Fiscal years end Jan. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jul 3, 2026) (EXEL)

P/E 18.8x · P/S 6.6x · P/FCF 13.8x · P/B 8.8x · FCF yield 7.25% · Earnings yield 5.32% · Buyback yield (TTM) 6.89%

P/E at fiscal year-ends: Jan 2026 14.9x, Jan 2025 18.8x, Dec 2023 37.1x.

Superinvestors (SEC 13F-HR, Q2 2026) (EXEL)

1 of 80 tracked investors hold EXEL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (EXEL)

4 of 10 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (EXEL)

Consensus Hold (mean 2.67 on a 1–5 scale), 18 analysts; mean target USD 55.53 (low 41, high 70).

Rating changes, last 120 days:

Total return (dividends reinvested) (EXEL)

Companies that name EXEL in their SEC reports

EXEL analyst estimates and revisions

EXEL options: expected move

Options price a move of about ±9.8% (±$6.45) by Nov 20, 2026, which includes earnings on Oct 29, 2026.

30-day implied volatility 46.6% vs 22.6% realized over the last 30 trading days. Put/call ratio (volume) 0.09. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:24 UTC)

Technical Analysis (EXEL)

Nexqual's technical model rates EXEL "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.

Analyst Ratings (EXEL)

Wall Street analysts rate EXEL "Hold" based on 18 analysts, with a mean price target of USD 55.53 (range USD 41–70), per Nexqual as of October 23, 2026 at 09:24 UTC.

Earnings (EXEL)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:24 UTC.

Financials & Fundamentals (EXEL)

Source: Nexqual, October 23, 2026 at 09:24 UTC.

Financial Health Score (EXEL)

Nexqual rates Exelixis, Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:24 UTC.

Ownership (EXEL)

Source: Nexqual, October 23, 2026 at 09:24 UTC.

Leadership (EXEL)

Exelixis, Inc. is led by Michael M. Morrissey, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.

Major Backers & Investors (EXEL)

Notable institutional backers of Exelixis, Inc. include Farallon Capital Management LLC, Renaissance Technologies, AQR Capital Management, LLC, according to Nexqual as of October 23, 2026 at 09:24 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:24 UTC.

From Exelixis, Inc.'s Latest SEC 10-K Filing (filed 2026-02-10)

Key Strengths & Strategy (as disclosed to the SEC)

• In December 2025, we submitted a New Drug Application (NDA) to the FDA for zanzalintinib in combination with atezolizumab for the treatment of previously treated metastatic colorectal cancer.
• In consideration for the exclusive license and other rights contained in the collaboration agreement, including commercialization rights in Canada, Ipsen paid us aggregate upfront payments of $210.0 million in 2016.

Partnerships

• Accordingly, and consistent with our historical agreement with GSK, we are required to pay a 3% royalty to Royalty Pharma on total net sales of any product containing cabozantinib, including net sales by Ipsen.
• Consistent with our historical agreement with GSK, we are required to pay a 3% royalty to Royalty Pharma on total net sales of any product containing cabozantinib, including net sales by Takeda.

Legal & Regulatory Risks (Item 1A, quoted)

• We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.
• We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.
• Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.
• The timing of the entrance of generic competitors to CABOMETYX and legislative and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S. could limit the revenue we derive from our products, most notably CABOMETYX, which could have a material adverse impact on our business, financial condition and results of operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt